semaglutide and fda Oral Gets Approval for CV Event Reduction in High-risk Diabetes Patients FDA warns consumers not to

When metabolic stress improves, some patients may experience fewer flares or less severe symptoms

Safety Advisory : Retatrutide remains an investigational agent under study and is not approved by the FDA or other major regulatory authorities for general clinical use

(vii) reduce the production/secretion of tumor necrosis factor alpha (TNF-), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1/CCL2), plasminogen activator inhibitor type 1 (PAI-1), transforming growth factor beta-1 (TGF-1) and angiotensinogen, while it can stimulate the secretion/activity of adiponectin

They may experience more energy, better mobility, and fewer health concerns related to diabetes